MedTrace Logo

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

NCT01965145 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-01-03

No results posted yet for this study

Summary

The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis exacerbations

Conditions

  • Behcet's Uveitis

Interventions

DRUG

Gevokizumab

Sterile solution administered subcutaneously

DRUG

Placebo

Sterile solution administered subcutaneously

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    lead OTHER

Principal Investigators

  • Sung Chul LEE, Pr · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-07-31
Completion
2015-09-30

Countries

  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01965145 on ClinicalTrials.gov